Literature DB >> 24844359

Repressed BMP signaling reactivates NKL homeobox gene MSX1 in a T-ALL subset.

Stefan Nagel1, Stefan Ehrentraut, Corinna Meyer, Maren Kaufmann, Hans G Drexler, Roderick A F MacLeod.   

Abstract

In T-cell acute lymphoblastic leukemia (T-ALL), several members of the NK-like (NKL) homeobox genes are aberrantly expressed. Here, we have analyzed the activity of NKL homeobox gene MSX1 using pediatric T-ALL in silico data, detecting overexpression in 11% of patients. Quantification of MSX1 transcripts in a panel of 24 T-ALL cell lines demonstrated overexpression in two examples. Comparative expression profiling indicated inhibition of the bone morphogenetic protein (BMP) signaling pathway, which was shown to inhibit MSX1 transcription. In the LOUCY cell line we identified conspicuous expression of CHRDL1 encoding a BMP inhibitor which mediated activation of MSX1. Promoter analyses demonstrated activation of CHRDL1 by oncogenic PITX1. Furthermore, knockdown and overexpression studies of hematopoietic transcription factors demonstrated that GATA2 and FOXC1 mediate activation and GATA3, LEF1, TAL1 and TOX repression of MSX1 transcription. Collectively, our findings suggest that MSX1 is physiologically restricted to lymphoid progenitors. The identification of deregulated BMP signaling may provide novel therapeutic options for the treatment of T-ALL.

Entities:  

Keywords:  BMP pathway; T-ALL; homeobox; lymphopoiesis

Mesh:

Substances:

Year:  2014        PMID: 24844359     DOI: 10.3109/10428194.2014.924119

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma.

Authors:  Stefan Nagel; Corinna Meyer; Maren Kaufmann; Hans G Drexler; Roderick A F MacLeod
Journal:  Oncotarget       Date:  2015-11-24

2.  Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Maren Kaufmann; Hans G Drexler; Roderick A F MacLeod
Journal:  Oncotarget       Date:  2016-07-19

3.  NKL homeobox gene activities in hematopoietic stem cells, T-cell development and T-cell leukemia.

Authors:  Stefan Nagel; Claudia Pommerenke; Michaela Scherr; Corinna Meyer; Maren Kaufmann; Karin Battmer; Roderick A F MacLeod; Hans G Drexler
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

Review 4.  A narrative review of the roles of muscle segment homeobox transcription factor family in cancer.

Authors:  Chao Liu; Mengxi Huang; Chao Han; Huiyu Li; Jing Wang; Yadi Huang; Yanyan Chen; Jialong Zhu; Gongbo Fu; Hanqing Yu; Zengjie Lei; Xiaoyuan Chu
Journal:  Ann Transl Med       Date:  2021-05

5.  Aberrantly Expressed OTX Homeobox Genes Deregulate B-Cell Differentiation in Hodgkin Lymphoma.

Authors:  Stefan Nagel; Stefan Ehrentraut; Corinna Meyer; Maren Kaufmann; Hans G Drexler; Roderick A F MacLeod
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

6.  NKL homeobox gene MSX1 acts like a tumor suppressor in NK-cell leukemia.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Maren Kaufmann; Roderick A F MacLeod; Hans G Drexler
Journal:  Oncotarget       Date:  2017-06-21

Review 7.  Research progress on the forkhead box C1.

Authors:  Jinhua Wang; Wan Li; Xiangjin Zheng; Xiaocong Pang; Guanhua Du
Journal:  Oncotarget       Date:  2017-11-20

8.  Aberrant activity of NKL homeobox gene NKX3-2 in a T-ALL subset.

Authors:  Stefan Nagel; Corinna Meyer; Maren Kaufmann; Margarete Zaborski; Roderick A F MacLeod; Hans G Drexler
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

9.  Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Maren Kaufmann; Roderick A F MacLeod; Hans G Drexler
Journal:  Oncotarget       Date:  2018-02-16

10.  NKL homeobox gene activities in B-cell development and lymphomas.

Authors:  Stefan Nagel; Roderick A F MacLeod; Corinna Meyer; Maren Kaufmann; Hans G Drexler
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.